{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-020831","form_type":"8-K","ticker":"KURA","cik":"0001422143","company_name":"Kura Oncology, Inc.","filed_at":"2025-02-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.591694+00:00","generated_at":"2026-05-27T02:31:31.766515+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Kura Oncology reports positive Phase 2 KOMET-001 trial of ziftomenib in R/R NPM1-m AML","bullets":["KOMET-001 achieved primary endpoint CR+CRh with statistical significance; benefit-risk profile encouraging.","NDA submission to FDA for ziftomenib in R/R NPM1-m AML on track for Q2 2025.","Plans to initiate two Phase 3 frontline trials (KOMET-017) in 2H 2025 with dual-primary endpoints for potential accelerated and full approval.","Multiple data presentations expected in 2025 across ziftomenib, KO-2806, and tipifarnib programs.","Collaboration with Kyowa Kirin continues for commercialization."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-020831","json":"https://secwatch.observer/filing/0001193125-25-020831.json","markdown":"https://secwatch.observer/filing/0001193125-25-020831.md","text":"https://secwatch.observer/filing/0001193125-25-020831.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1422143/000119312525020831/0001193125-25-020831-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1422143/000119312525020831/d886608d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T02:31:31.766515+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}